By FB Financial has announced a notable increase in profit for the second quarter of the year. With a stronger capital base, the parent company of FirstBank witnessed a remarkable 14% rise in shares, reaching $34.50 in after-hours trading.
Masimo Adjusts Revenue Guidance
Patient monitoring technologies manufacturer, Masimo, has revised its full-year revenue guidance due to the expected shortfall in second-quarter revenue. Consequently, shares dropped by 24% to $111.80 in after-hours trading.
Acumen Pharmaceuticals Initiates Public Offering
In an effort to raise funds, Acumen Pharmaceuticals has commenced an underwritten public offering of $100 million for its common stock. However, the clinical-stage biopharmaceutical company’s stock experienced a decline of 9.5%, settling at $8.80 in after-hours trading.
CEL-SCI Plans Common Stock Sale
CEL-SCI has announced its intention to sell common stock; however, details such as the number of shares and price range are yet to be disclosed. Consequently, shares of the cancer immunotherapy company dropped by 18% to $2.34 in after-hours trading.
Karyopharm Therapeutics Receives Fast Track Designation
Karyopharm Therapeutics has been granted fast track designation from the Food and Drug Administration (FDA) for its innovative rare blood cancer treatment. As a result, shares of the pharmaceutical company experienced a significant 7.2% increase, reaching $1.64 in after-hours trading.
Comments